Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #GWHI--Hologic Releases Results of Inaugural Global Women's Health Index – First Study Representing the Health of 2.5 Billion Women and Girls

Hologic Releases Results of Inaugural Global Women's Health Index – First Study Representing the Health of 2.5 Billion Women and Girls

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences

Anthem

Hologic, Inc. (NASDAQ:HOLX) is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

Assessing Hologic Stock After the Anthem Alliance

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Hologic (HOLX) Up 5.7% Since Last Earnings Report: Can It Continue?

American Tower

Amazon

Comcast

Danaher

Flowers Foods

Manhattan Associates

Microsoft

Republic Services

Visa

If you're into ESG investing and are looking for stocks to buy, Morningstar created a portfolio of ESG mutual funds. Here are 10 solid ideas.

10 Best Stocks to Buy if ESG Investing Is Your Thing

Hologic's (HOLX) Acessa Procedure's new coverage upholds Laparoscopic Radiofrequency Ablation for women suffering from uterine fibroids.

Hologic (HOLX) Acessa Procedure Gets Anthem Insurance Coverage

Overall, nine out of the 15 Exec Comp Aligned with ROIC Stocks outperformed the S&P 500 from July 15, 2021 through August 11, 2021.

A Quality Exec Comp Plan Lowers The Risk Of Investing In Hologic

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that Anthem Blue Cross Blue Shield, the second largest health plan in the United States, has updated its medical policy to cover Radiofrequency Ablation (LAP-RFA), which includes the Acessa® procedure (CPT Code 58674), for women suffering from uterine fibroids. The updated policy creates access to uterine-preserving care for Anthem's approximately 40 million members in all 50 st

Anthem, Nation's Second Largest Health Plan, Now Covers Hologic's Acessa Procedure as a Treatment for Uterine Fibroids

Hologic is a leading medical technology company that's carved out a niche in the Women's Health segment.

Hologic: Prepare For Takeoff

Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.

Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull

Hologic, Inc.'s (HOLX) CEO Stephen MacMillan on Q3 2021 Results - Earnings Call Transcript

Shares of Hologic (NASDAQ:HOLX) increased after the company reported Q3 results. Quarterly Results Earnings per share were up 77.33% year over year to $1.33, which beat the estimate of $1.12.

Recap: Hologic Q3 Earnings

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for Third Quarter of Fiscal 2021

Hologic Announces Financial Results for Third Quarter of Fiscal 2021

Companhia Energetica de Minas Gerais

Sprouts Farmers Markets

Investors may want to consider the three non-cyclical stocks listed below, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are doubling the 20-year high quality market corporate bond spot rate of 3.23% as of the writing of this article.

A Trio of High Return Non-Cyclical Stock Picks

The acquisition of Biotheranostics and relaunch of Brevera are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the third quarter.

Breast Health Sales to Aid Hologic's (HOLX) Q3 Earnings

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #CDC--New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs)

New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium

Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its third-quarter performance.

Hologic (HOLX) to Report Q3 Earnings: What's in the Cards?

The stock price of Hologic, a medical devices company focused on women's health, has seen a 7% rise over the last twenty-one trading days, while it is up just 12% over the last year. Hologic has benefited from an increase in its installed base of Panther systems, after the U.S. FDA approved.

Will Hologic Stock Grow Further After A 7% Rise In A Month?

Per Hologic (HOLX), saliva collection is noninvasive and painless. The availability of this alternative specimen type should facilitate screening at schools, workplaces and other settings.

Hologic (HOLX) COVID Test With Saliva Sample Gets CE Mark

Hologic Inc (NASDAQ: HOLX) has obtained a CE Mark to use saliva samples with its Aptima SARS-CoV-2 assay in Europe.  The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the pathogen's genetic material causing COVID-19.

European OK's Use Of Saliva Samples With Hologic's Aptima COVID-19 Test

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Amalgamated Financial Corp

Cigna

America's Car-Mart

D.R. Horton

Federated Hermes

Turtle Beach

Labcorp Holdings Inc

Lumber Liquidators

Zumiez

To call a beautiful woman a “Perfect 10” these days would be considered chauvinistic and outdated.

The Perfect 10 Portfolio Returned 69% Last Year

Clorox

Cabot Oil & Gas

Quest Diagnostics

Gilead Sciences

Merck

Pfizer

PerkinElmer

Regeneron Pharmaceuticals

Texas Instruments

The shares of these S&P 500 companies are not only priced right—they also could hold up better during volatility.

11 Quality Stocks That Are Relatively Cheap

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Announce Financial Results for the Third Quarter of Fiscal 2021 on Wednesday, July 28, 2021.

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2021 on Wednesday, July 28, 2021

Hologic's (HOLX) Aptima CMV Quant assay is intended to help in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients.

News for Hologic Stock (HOLX)